Synopsis of recent research by authors named "Ryo Ishino"
- Ryo Ishino's research focuses on the application of oncolytic herpes simplex virus type 1 (HSV-1) for treating hematological malignancies, specifically plasma cell neoplasms, exploring its direct anti-tumor effects and immune-mediated mechanisms.
- In a study, the third-generation oncolytic HSV-1, T-01, demonstrated a significant direct oncolytic effect against multiple human myeloma cell lines in vitro, highlighting its potential for melanoma and other malignancies.
- Another article revealed that T-01 infected and effectively killed a notable percentage of both human cell lines and primary cells from various types of hematological malignancies, indicating its broadened applicability in cancer therapy.
